Fierce Healthcare

MAY 14, 2023

Industry Voices—The case for hospitals to invest in cleaner air pminemyer Sun, 05/14/2023 - 23:25

Hospitals 131

Hospitals 131

pharmaphorum

MAY 14, 2023

FDA advisors narrowly back Sarepta’s Duchenne gene therapy Phil.

FDA 95

FDA 95

BioPharm

MAY 14, 2023

Time to results can be significantly reduced with the use of RapidFire high-throughput mass spectrometry (MS). With this technique, a lab’s next great innovation can be brought from conception to reality in a timely and efficient manner.

40

40

PharmaShots

MAY 14, 2023

Shots: LaNova Medicines will receive an up front and near-term fees of ~$55M and is eligible to receive additional development and commercial milestones of ~$545M along with royalties on net sales globally AstraZeneca to get an exclusive license globally to research, develop, and commercialize LM-305, a pre-clinical stage ADC targeting G protein-coupled receptor, class C, group 5, member D (GPRC5D) The collaboration focuses on discovering and developing innovative therapies in ADC and Immuno-Onc

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Med Ed 101

MAY 14, 2023

A week ago or so I released the MPJE Master 2nd Edition Ebook. The PAPERBACK Edition is now available. You can literally get a 150+ page book for less than 5$. I will end this initial offer to my followers this week and the price will increase significantly. There are a ton of updates from […] The post 150+ Page Paperback MPJE Book For Less Than 5$ – Ending Soon!

40

40

pharmaphorum

MAY 14, 2023

After FDA snub, DBV charts a new course for Viaskin peanut Phil.

FDA 52

FDA 52